Sun Pharmaceutical Industries has received US Food and Drug Administration (US FDA) approval for Sanfoi’s DDAVP nasal Spray Generic, which is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.
https://www.epicresearch.co/
No comments:
Post a Comment